Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2008 1
2010 2
2011 4
2012 3
2013 3
2014 5
2015 1
2016 2
2017 1
2018 3
2019 3
2020 1
2021 6
2022 7
2023 12
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps.
Berger P, Menzies-Gow A, Peters AT, Kuna P, Rabe KF, Altincatal A, Soler X, Pandit-Abid N, Siddiqui S, Jacob-Nara JA, Deniz Y, Rowe PJ. Berger P, et al. Among authors: altincatal a. Ann Allergy Asthma Immunol. 2023 Feb;130(2):215-224. doi: 10.1016/j.anai.2022.11.006. Epub 2022 Nov 7. Ann Allergy Asthma Immunol. 2023. PMID: 36356712 Free article. Clinical Trial.
Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction.
Hanania NA, Castro M, Bateman E, Pavord ID, Papi A, FitzGerald JM, Maspero JF, Katelaris CH, Singh D, Daizadeh N, Altincatal A, Pandit-Abid N, Soler X, Siddiqui S, Laws E, Jacob-Nara JA, Rowe PJ, Lederer DJ, Hardin M, Deniz Y. Hanania NA, et al. Among authors: altincatal a. Ann Allergy Asthma Immunol. 2023 Feb;130(2):206-214.e2. doi: 10.1016/j.anai.2022.10.018. Epub 2022 Nov 2. Ann Allergy Asthma Immunol. 2023. PMID: 36332763 Free article. Clinical Trial.
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma.
Papi A, Castro M, Corren J, Pavord ID, Tohda Y, Altincatal A, Pandit-Abid N, Laws E, Akinlade B, Mannent LP, Gall R, Jacob-Nara JA, Deniz Y, Rowe PJ, Lederer DJ, Hardin M. Papi A, et al. Among authors: altincatal a. Respir Med. 2024 Apr;224:107535. doi: 10.1016/j.rmed.2024.107535. Epub 2024 Jan 23. Respir Med. 2024. PMID: 38272376 Free article.
Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics.
Hersh CM, Altincatal A, Belviso N, Kapadia S, de Moor C, Rudick R, Williams JR, Miller C, Koulinska I. Hersh CM, et al. Among authors: altincatal a. Mult Scler J Exp Transl Clin. 2022 Jan 7;8(1):20552173211069852. doi: 10.1177/20552173211069852. eCollection 2022 Jan-Mar. Mult Scler J Exp Transl Clin. 2022. PMID: 35024161 Free PMC article.
Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma.
Corren J, Katelaris CH, Castro M, Maspero JF, Humbert M, Halpin DMG, Altincatal A, Pandit-Abid N, Soler X, Radwan A, Jacob-Nara JA, Deniz Y, Rowe PJ. Corren J, et al. Among authors: altincatal a. ERJ Open Res. 2023 Oct 16;9(5):00037-2023. doi: 10.1183/23120541.00037-2023. eCollection 2023 Sep. ERJ Open Res. 2023. PMID: 37859672 Free PMC article.
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Reder AT, Centonze D, Naylor ML, Nagpal A, Rajbhandari R, Altincatal A, Kim M, Berdofe A, Radhakrishnan M, Jung E, Sandrock AW, Smirnakis K, Popescu C, de Moor C. Reder AT, et al. Among authors: altincatal a. CNS Drugs. 2021 Mar;35(3):317-330. doi: 10.1007/s40263-021-00804-1. Epub 2021 Mar 20. CNS Drugs. 2021. PMID: 33743151 Free PMC article.
46 results